What is the Mprize?
The Mprize consists of two separate prize competitions, both of which are judged by our scientific advisory board:
In the competition for the Longevity Prize, money is awarded to the producer of the world's oldest-ever mouse. This is restricted to the species used in virtually all laboratory work, Mus musculus, but no other restrictions should be placed on the way in which the mouse's lifespan is extended, provided that the methods used maintain cognitive and physical wellbeing.
The amount won by a winner of the Longevity Prize is in proportion to the size of the fund at that time, but also in proportion to the margin by which the previous record is broken.
The Rejuvenation Prize rewards successful late-onset interventions performed on an aged mouse and has been instituted to satisfy two shortcomings of the Longevity Prize: first, it is of limited scientific value to focus on a single mouse (a statistical outlier); and second, it is very likely that interventions applied throughout life (as they are during Longevity Prize research) will always be ahead of those initiated late, and thus would have an ongoing advantage in a simple competition structure. Our most important end goal is not merely to extend life, but to promote the development of interventions that restore youthful physiology. By seeking interventions that are effective when initiated at a late age, this prize encourages scientific research that is most likely to benefit those reading these guidelines today.
The Rejuvenation Prize is not awarded for the life extension of an individual mouse but for a published, peer-reviewed study. The study must satisfy the following criteria:
The amount won by a successful new Rejuvenation Prize record is calculated in the same way as for the Longevity Prize, but is only awarded upon publication of the study in question.
Competitor Bruce Teter
In the study by Stephen Spindler at UC Riverside, testing two doses of curcumin in the Longvida formulation, the mice are still surviving at about 80%, so it is too early to tell compared to untreated mice, and although calorie restricted (CR) mice are 90-95% surviving at this age, it is too early to tell if curcumin is different than CR. It will be several months before enough mice have died (usually at the point of 50% mortality in untreated, control mice). For the NIA ITP study of pure curcumin, it will be about 2 months before 50% mortality in the control mice, at which point the analysis of median life span extension will be made.
Also, I am organizing clinical trials of curcumin in the bioavailable Longvida formulation for treating age related diseases. The Longvida formulation recently became commercially available.